Edwards Lifesciences stock slips after Medicare TAVR decision as analysts reaffirm upside
Published on 09/11/2026 at 23:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edwards Lifesciences stock (ISIN US28176E1082) is trading at USD 84.31 on the New York Stock Exchange on September 11, 2026, down about 2.8 percent intraday from the previous close of USD 86.77 as investors digest a key Medicare coverage decision for transcatheter aortic valve replacement procedures.
Medicare TAVR coverage update and guidance
On September 10, 2026, the Centers for Medicare and Medicaid Services (CMS) published an updated national coverage determination for transcatheter aortic valve replacement (TAVR), a core therapy in Edwards Lifesciences’ portfolio, after a reconsideration process requested by the company.GuruFocus reports that the new policy removes prior evidence development requirements for symptomatic severe aortic valve stenosis and broadens access by extending coverage to certain asymptomatic severe cases under evidence development frameworks.
According to GuruFocus on September 10, 2026, Edwards Lifesciences reaffirmed its 2026 guidance alongside the coverage decision, projecting sales growth of 10 to 11 percent for the year and earnings per share between USD 2.95 and USD 3.05.
Stock reaction and valuation context
Per Nasdaq data relayed by Yahoo Finance on September 11, 2026, Edwards Lifesciences shares trade at USD 84.31 as of 1:18 p.m. Eastern time, about 2.8 percent below the previous closing price of USD 86.77 on September 10, 2026, after opening at USD 87.51 earlier in the session.
The same overview shows a trailing year-to-date total return of 1.06 percent for Edwards Lifesciences versus roughly 12.0 percent for the S&P 500 index, indicating the stock has significantly lagged the broader US equity market so far in 2026.Yahoo Finance also cites a current share price of USD 84.31 against an average analyst target of USD 100.96, implying upside of about 19.8 percent if consensus forecasts are met.
Latest quarterly figures support analyst optimism
In its most recent quarterly report, Edwards Lifesciences delivered results that exceeded market expectations, reinforcing the positive view many analysts hold on the stock.MarketBeat notes that Edwards reported earnings per share of USD 0.78 for the latest quarter, beating the analyst consensus of USD 0.74 by USD 0.04, while quarterly revenue came in at USD 1.74 billion compared with expectations of USD 1.70 billion.
According to the same analysis from MarketBeat on September 11, 2026, Edwards Lifesciences’ revenue increased 13.6 percent year over year in that quarter, illustrating robust growth relative to the prior-year period and underlining why the company expects double-digit sales expansion for the full fiscal year 2026.
Analyst ratings and price targets
Analyst sentiment on Edwards Lifesciences remains broadly positive following the Medicare decision and the latest earnings beat. As MarketBeat reported on September 11, 2026, BTIG Research reaffirmed its Buy rating on Edwards Lifesciences and maintained a price target of USD 110 per share.
The BTIG target of USD 110, based on MarketBeat’s commentary, implies about 26.9 percent upside from an opening price of USD 86.69 cited in the same report, underscoring the extent to which some analysts see room for the shares to recover from recent underperformance.MarketBeat adds that 17 analysts rate Edwards Lifesciences a Buy and six rate it a Hold, yielding a consensus rating of Moderate Buy and an average price target of USD 100.27.
Separate coverage from The Globe and Mail on September 11, 2026, citing TipRanks data, notes that Citi analyst Joanne Wuensch has maintained a Buy rating on Edwards Lifesciences and set a price target of USD 110, aligned with BTIG’s view.
At the same time, not all houses see the shares as undervalued at current levels. Investing.com reported on September 11, 2026, that Canaccord has reiterated a Hold rating on Edwards Lifesciences with a price target of USD 85.
In that note highlighted by Investing.com, the firm points out that Edwards Lifesciences’ stock trades around USD 86.77 with a market capitalization of about USD 50 billion and a price-earnings ratio of 51.54, reflecting a premium valuation that tempers its stance despite the favorable Medicare coverage outcome.
Market perception of the Medicare decision
The immediate share price reaction suggests investors are still calibrating the long-term impact of the updated Medicare TAVR coverage. An analysis from Quiver Quantitative on September 11, 2026, notes that Edwards Lifesciences shares are down roughly 3.0 percent and attributes the move to a muted or sell-the-news response to the Medicare update rather than to any new negative company-specific data.
That interpretation is consistent with the company’s own positioning of the decision as a positive for patient access and with the reaffirmed full-year guidance for 10 to 11 percent sales growth and EPS between USD 2.95 and USD 3.05.GuruFocus describes Edwards Lifesciences as expressing strong support for the national coverage determination and highlights that the company sees the policy as broadening access to its TAVR therapy.
From a valuation standpoint, GuruFocus calculates that Edwards Lifesciences shares trade at USD 86.77, about 9.0 percent below its GF Value estimate of USD 95.33, suggesting moderate undervaluation according to that proprietary measure despite a premium price-earnings ratio relative to the company’s historical median.
Risks and what investors focus on now
For investors, the updated Medicare coverage framework reduces regulatory uncertainty around TAVR reimbursement but does not eliminate broader risks linked to healthcare policy and competitive dynamics in structural heart interventions. Coverage rules for asymptomatic patients still involve evidence-development requirements, and reimbursement levels for hospitals and physicians can influence adoption rates and procedural volumes.
Analyst commentary referenced by Investing.com suggests that valuation is a key counterweight to the strong growth story: at a price-earnings ratio above 50 based on recent earnings, Edwards Lifesciences may have less room for multiple expansion if sales growth or margin trends were to soften.
Against that backdrop, the quantified comparison between guidance and current price targets is central. Management’s projection of 10 to 11 percent sales growth in 2026 and EPS between USD 2.95 and USD 3.05 sits alongside an average analyst price target of about USD 100.96 and high targets at USD 110, while the stock trades near USD 84.31, several percent below both the GF Value estimate of USD 95.33 and the consensus target.
Stock price and trading data
Edwards Lifesciences stock most recently closed at USD 86.77 on the New York Stock Exchange on September 10, 2026, and trades around USD 84.31 intraday on September 11, 2026, according to price data from Nasdaq relayed by Yahoo Finance.
Edwards Lifesciences stock facts
- Company: Edwards Lifesciences Corporation
- ISIN: US28176E1082
- Ticker: EW
- Trading venue: NYSE
- Price (as of September 11, 2026, 13:18): 84.31 USD
- Market capitalization: 50,000,000,000 USD (as of September 11, 2026)
- Sector / Industry: Health Care / Medical Devices
- Index membership: S&P 500
